Published in Diabetes Care on September 01, 2014
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context (2015) 0.93
Sulfonylureas: Assets in the past, present and future. Indian J Endocrinol Metab (2015) 0.92
Impact on glycated haemoglobin of a biological response-based measure of medication adherence. Diabetes Obes Metab (2015) 0.83
Incretin-Based Therapy and Risk of Pancreatic Cancer in Patients with Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Controlled Trials. Diabetes Ther (2016) 0.82
IDegLira Versus Insulin Glargine U100: A Long-term Cost-effectiveness Analysis in the US Setting. Diabetes Ther (2017) 0.78
The "Evidence" Is In! It Does Get Better! Diabetes Care (2015) 0.77
Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. J Diabetes Complications (2015) 0.75
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr Metab (Lond) (2016) 0.75
Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists. Diabetes Metab Syndr Obes (2017) 0.75
A Real-world Study of Treatment Patterns and Outcomes in US Managed-Care Patients With Type 2 Diabetes Initiating Injectable Therapies. Diabetes Obes Metab (2016) 0.75
Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial. Diabetes Obes Metab (2015) 0.75
Advances in the treatment of type 2 diabetes: impact of dulaglutide. Diabetes Metab Syndr Obes (2016) 0.75
Ten-Year Trends in the Morbidity of Diabetes Mellitus and Antidiabetic Drug Utilization in Croatia: A Study Based on Routinely Collected Data. Int J Family Med (2016) 0.75
Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes (2017) 0.75
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 15.76
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ (2000) 10.66
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Thiazolidinediones. N Engl J Med (2004) 9.42
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (2009) 9.32
The biology of incretin hormones. Cell Metab (2006) 8.92
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med (2007) 8.31
Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care (2006) 7.99
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract (2009) 7.06
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet (2008) 6.91
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care (2008) 5.94
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet (2007) 5.74
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology (2011) 4.99
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA (2006) 4.90
AACE comprehensive diabetes management algorithm 2013. Endocr Pract (2013) 4.88
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care (2006) 4.75
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med (2013) 4.25
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care (2008) 4.20
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev (2007) 3.69
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology (2004) 3.57
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care (2009) 3.50
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care (2012) 3.28
Second-line agents for glycemic control for type 2 diabetes: are newer agents better? Diabetes Care (2014) 2.99
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther (2009) 2.96
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care (2007) 2.92
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med (2007) 2.89
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia (2006) 2.82
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin (2009) 2.68
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab (2011) 2.68
Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid (2010) 2.48
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care (2010) 2.39
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology (2010) 2.33
Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med (2012) 2.13
Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes (2009) 2.10
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev (2008) 2.10
Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab (2003) 2.04
Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care (2014) 2.04
A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med (2011) 2.01
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther (2008) 1.97
Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med (2011) 1.97
Pancreatic safety of incretin-based drugs--FDA and EMA assessment. N Engl J Med (2014) 1.95
Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia (2009) 1.92
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J (2013) 1.92
Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. N Engl J Med (2010) 1.91
A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe? Diabetes Care (2013) 1.90
Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation (1997) 1.80
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care (2009) 1.80
Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials. Diabetes Obes Metab (2013) 1.71
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. J Clin Endocrinol Metab (2010) 1.68
Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol (2013) 1.67
Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes (2009) 1.62
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care (2014) 1.60
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord (2010) 1.60
Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev (2001) 1.58
Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med (2012) 1.57
Beta-cell replication is increased in donor organs from young patients after prolonged life support. Diabetes (2010) 1.55
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care (2013) 1.51
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract (2006) 1.50
Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab (2008) 1.49
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract (2009) 1.47
Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev (2006) 1.47
Exenatide and rare adverse events. N Engl J Med (2008) 1.46
The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes (2012) 1.44
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin (2007) 1.43
A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab (2011) 1.42
Trends in use of oral hypoglycemic agents 1964-1986. Diabetes Care (1989) 1.42
GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab (2011) 1.40
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res (2013) 1.36
Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev (2006) 1.35
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab (2009) 1.32
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab (2010) 1.28
Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci (2005) 1.27
Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des (2005) 1.27
Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab (2010) 1.22
Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA (1971) 1.19
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. J Clin Endocrinol Metab (2011) 1.16
Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab (2007) 1.14
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care (2015) 3.80
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet (2013) 2.66
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care (2014) 2.20
Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care (2014) 2.17
Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care (2014) 2.04
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care (2014) 1.95
Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care (2013) 1.56
Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin (2008) 1.52
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. Diabetes Care (2016) 1.29
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. Diabetes Care (2015) 1.12
Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care (2016) 0.97
Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5. Diabetes Care (2015) 0.91
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes Care (2015) 0.90
Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. Diabetes Care (2015) 0.90
Insulin Dose and Cardiovascular Mortality in the ACCORD Trial. Diabetes Care (2015) 0.89
Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. Am Heart J (2016) 0.88
Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care (2015) 0.85
Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. Diabetes Care (2015) 0.81
Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. Am J Med (2015) 0.79
Effect of relative weight group change on nuclear magnetic resonance spectroscopy derived lipoprotein particle size and concentrations among adolescents. J Pediatr (2014) 0.79
Effect of exogenous intravenous administrations of GLP-1 and/or GIP on circulating pro-atrial natriuretic peptide in subjects with different stages of glucose tolerance. Diabetes Care (2015) 0.77
Response to comment on Balkau et al. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care 2014;37:2108-2113. Diabetes Care (2014) 0.75
Response to comment on Home et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes care 2014;37:1499-1508. Diabetes Care (2014) 0.75
Response to comment on Cefalu et Al. The alarming and rising costs of diabetes and prediabetes: a call for action! Diabetes care 2014;37:3137-3138. Diabetes Care (2015) 0.75
The War Is Not Yet Won. Diabetes Care (2017) 0.75
Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial. Diabetes Care (2017) 0.75
Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial. Diabetes Care (2016) 0.75
Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care 2016;39:1186-1201. Diabetes Care (2017) 0.75
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care (2017) 0.75
Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care (2017) 0.75
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care (2019) 0.75